Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;124(1-3):36-42.
doi: 10.1016/j.schres.2010.08.039. Epub 2010 Sep 24.

Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)

Affiliations

Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)

Courtney Forbes et al. Schizophr Res. 2010 Dec.

Abstract

As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Dr. Blanchard has received honorarium from Merck for consultation. Dr. Gur has received investigator initiated grants from Astra Zeneca and Pfizer; honorarium from Astra Zeneca and Pfizer for a lecture and from Merck for consultation.

Similar articles

Cited by

References

    1. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale. Schizophr Res. 1996;19:205–212. - PubMed
    1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247–251. - PubMed
    1. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms in schizophrenia. Psychopharmacol Bull. 1989;25:159–163. - PubMed
    1. Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry. 1982;39:784–788. - PubMed
    1. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS) Iowa City, IA: The University of Iowa; 1984.

Publication types

MeSH terms